vs
Side-by-side financial comparison of GENESCO INC (GCO) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $616.2M, roughly 1.0× GENESCO INC). Royalty Pharma plc runs the higher net margin — 34.4% vs 0.9%, a 33.6% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs 3.3%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs -8.7%).
Genesco Inc. is an American publicly owned specialty retailer of branded footwear and accessories and is a wholesaler of branded and licensed footwear based in Nashville, Tennessee. Founded back in 1924 as Jarman Shoe Company, a footwear manufacturer, the company changed its name to General Shoe Corporation in 1933, and became a public company in 1939. By 1957, its stock would be included in the first S&P 500 Index. The company took its current name, Genesco—an acronym derived from its earlie...
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
GCO vs RPRX — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $616.2M | $622.0M |
| Net Profit | $5.4M | $214.2M |
| Gross Margin | 46.8% | — |
| Operating Margin | 1.4% | 62.4% |
| Net Margin | 0.9% | 34.4% |
| Revenue YoY | 3.3% | 4.8% |
| Net Profit YoY | 128.3% | 2.9% |
| EPS (diluted) | $0.50 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $616.2M | $622.0M | ||
| Q3 25 | $546.0M | $609.3M | ||
| Q2 25 | $474.0M | $578.7M | ||
| Q1 25 | $745.9M | $568.2M | ||
| Q4 24 | $596.3M | $593.6M | ||
| Q3 24 | $525.2M | $564.7M | ||
| Q2 24 | $457.6M | $537.3M | ||
| Q1 24 | $739.0M | $568.0M |
| Q4 25 | $5.4M | $214.2M | ||
| Q3 25 | $-18.5M | $288.2M | ||
| Q2 25 | $-21.2M | $30.2M | ||
| Q1 25 | $34.4M | $238.3M | ||
| Q4 24 | $-18.9M | $208.2M | ||
| Q3 24 | $-10.0M | $544.0M | ||
| Q2 24 | $-24.3M | $102.0M | ||
| Q1 24 | $27.2M | $4.8M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 45.8% | — | ||
| Q2 25 | 46.7% | — | ||
| Q1 25 | 46.9% | — | ||
| Q4 24 | 47.8% | — | ||
| Q3 24 | 46.8% | — | ||
| Q2 24 | 47.3% | — | ||
| Q1 24 | 46.3% | — |
| Q4 25 | 1.4% | 62.4% | ||
| Q3 25 | -2.6% | 70.1% | ||
| Q2 25 | -5.9% | 36.3% | ||
| Q1 25 | 6.2% | 94.0% | ||
| Q4 24 | 1.7% | 60.9% | ||
| Q3 24 | -2.0% | — | ||
| Q2 24 | -7.0% | 50.2% | ||
| Q1 24 | 5.0% | -13.0% |
| Q4 25 | 0.9% | 34.4% | ||
| Q3 25 | -3.4% | 47.3% | ||
| Q2 25 | -4.5% | 5.2% | ||
| Q1 25 | 4.6% | 41.9% | ||
| Q4 24 | -3.2% | 35.1% | ||
| Q3 24 | -1.9% | 96.3% | ||
| Q2 24 | -5.3% | 19.0% | ||
| Q1 24 | 3.7% | 0.8% |
| Q4 25 | $0.50 | $0.49 | ||
| Q3 25 | $-1.79 | $0.67 | ||
| Q2 25 | $-2.02 | $0.07 | ||
| Q1 25 | $3.16 | $0.55 | ||
| Q4 24 | $-1.76 | $0.46 | ||
| Q3 24 | $-0.91 | $1.21 | ||
| Q2 24 | $-2.23 | $0.23 | ||
| Q1 24 | $2.29 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.0M | $618.7M |
| Total DebtLower is stronger | $89.5M | $9.0B |
| Stockholders' EquityBook value | $513.8M | $9.7B |
| Total Assets | $1.5B | $19.6B |
| Debt / EquityLower = less leverage | 0.17× | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.0M | $618.7M | ||
| Q3 25 | $41.0M | $938.9M | ||
| Q2 25 | $21.7M | $631.9M | ||
| Q1 25 | $34.0M | $1.1B | ||
| Q4 24 | $33.6M | $929.0M | ||
| Q3 24 | $45.9M | $950.1M | ||
| Q2 24 | $19.2M | $1.8B | ||
| Q1 24 | $35.2M | $843.0M |
| Q4 25 | $89.5M | $9.0B | ||
| Q3 25 | $71.0M | $8.9B | ||
| Q2 25 | $121.0M | $8.0B | ||
| Q1 25 | $0 | $7.6B | ||
| Q4 24 | $100.1M | $7.6B | ||
| Q3 24 | $77.8M | $7.6B | ||
| Q2 24 | $59.4M | $7.6B | ||
| Q1 24 | $34.7M | $6.1B |
| Q4 25 | $513.8M | $9.7B | ||
| Q3 25 | $506.4M | $9.6B | ||
| Q2 25 | $522.2M | $9.5B | ||
| Q1 25 | $547.0M | $9.8B | ||
| Q4 24 | $516.9M | $10.3B | ||
| Q3 24 | $532.6M | $10.3B | ||
| Q2 24 | $548.5M | $9.8B | ||
| Q1 24 | $571.2M | $9.9B |
| Q4 25 | $1.5B | $19.6B | ||
| Q3 25 | $1.4B | $19.3B | ||
| Q2 25 | $1.4B | $18.3B | ||
| Q1 25 | $1.3B | $17.6B | ||
| Q4 24 | $1.4B | $18.2B | ||
| Q3 24 | $1.4B | $18.0B | ||
| Q2 24 | $1.3B | $17.7B | ||
| Q1 24 | $1.3B | $16.1B |
| Q4 25 | 0.17× | 0.92× | ||
| Q3 25 | 0.14× | 0.93× | ||
| Q2 25 | 0.23× | 0.84× | ||
| Q1 25 | 0.00× | 0.78× | ||
| Q4 24 | 0.19× | 0.74× | ||
| Q3 24 | 0.15× | 0.74× | ||
| Q2 24 | 0.11× | 0.78× | ||
| Q1 24 | 0.06× | 0.62× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-12.9M | $827.1M |
| Free Cash FlowOCF − Capex | $-31.5M | — |
| FCF MarginFCF / Revenue | -5.1% | — |
| Capex IntensityCapex / Revenue | 3.0% | — |
| Cash ConversionOCF / Net Profit | -2.41× | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | $23.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-12.9M | $827.1M | ||
| Q3 25 | $86.3M | $702.6M | ||
| Q2 25 | $-101.0M | $364.0M | ||
| Q1 25 | $117.0M | $596.1M | ||
| Q4 24 | $-23.1M | $742.5M | ||
| Q3 24 | $27.7M | $703.6M | ||
| Q2 24 | $-33.7M | $658.2M | ||
| Q1 24 | $118.3M | $664.6M |
| Q4 25 | $-31.5M | — | ||
| Q3 25 | $71.7M | — | ||
| Q2 25 | $-119.9M | — | ||
| Q1 25 | $103.3M | — | ||
| Q4 24 | $-36.2M | — | ||
| Q3 24 | $19.8M | — | ||
| Q2 24 | $-40.1M | — | ||
| Q1 24 | $107.8M | — |
| Q4 25 | -5.1% | — | ||
| Q3 25 | 13.1% | — | ||
| Q2 25 | -25.3% | — | ||
| Q1 25 | 13.8% | — | ||
| Q4 24 | -6.1% | — | ||
| Q3 24 | 3.8% | — | ||
| Q2 24 | -8.8% | — | ||
| Q1 24 | 14.6% | — |
| Q4 25 | 3.0% | — | ||
| Q3 25 | 2.7% | — | ||
| Q2 25 | 4.0% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 2.2% | — | ||
| Q3 24 | 1.5% | — | ||
| Q2 24 | 1.4% | — | ||
| Q1 24 | 1.4% | — |
| Q4 25 | -2.41× | 3.86× | ||
| Q3 25 | — | 2.44× | ||
| Q2 25 | — | 12.06× | ||
| Q1 25 | 3.40× | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | — | 1.29× | ||
| Q2 24 | — | 6.45× | ||
| Q1 24 | 4.35× | 139.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GCO
| Journeys Group Segment | $376.7M | 61% |
| Schuh Group Segment | $123.8M | 20% |
| Johnston And Murphy Group Segment | $81.2M | 13% |
| Genesco Brands Segment | $34.6M | 6% |
| Store Restructuring | $3.9M | 1% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
